StockData
BioNexus Gene Lab Corp logo

BioNexus Gene Lab Corp (BGLC) stock

BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3089% below fair value
$0.77−0.05 (-6.56%)

Close on Nov 17, 2026Market cap $2.25MP/E –Yield –

Earnings

BioNexus Gene Lab's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of BioNexus Gene Lab's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

BioNexus Gene Lab has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When BioNexus Gene Lab puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases BioNexus Gene Lab filed with the SEC as exhibits to Form 8-K or 6-K

  1. Update
  2. News
  3. News
  4. Update
  5. News
  6. News
  7. Update
  8. Update
  9. Update
  10. Update
  11. Update
  12. Update
  13. Update
  14. Update
  15. News

See a number that looks wrong?